ProCE Banner Activity

Mutations Predict Responses to mTOR Inhibitors in mRCC

Slideset Download
Conference Coverage
Mutations in MTOR, TSC1, and TSC2, but not PTEN or PIK3CA, were associated with complete responses to mTOR inhibitors in patients with metastatic RCC.

Released: June 04, 2015

Expiration: June 02, 2016

No longer available for credit.

Share

Provided by

Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC
ProCE Banner

Supporters

AstraZeneca

Bayer Healthcare Pharma

Bristol Myers Squibb

Celgene

Genentech BioOncology

Incyte

Novartis Pharmaceuticals Corporation